Objective To analyze characteristics of clinical trials of coronavirus disease 2019 (COVID-19) in China, find out possible problems, and provide reference for clinical trial designers and policy makers. Methods Clinical trial data for CONID-19 registered at official website of China Clinical Trial Registry and U. S. ClinicalTrials.gov before 24:00 on February 23, 2020 were collected, data were cleaned by Ducati Data Analyzer (DDA) software, and characteristic variables of clinical trials were described by SPSS 18.0. Results The first COVID-19 clinical trial registration date was on January 23, 2020, by the end of 24:00 of February 23, 2020, China has registered 240 COVID-19 clinical trials, including 62(25.83%) multi-center studies. A total of 157 institutions participated in the clinical trials, with the largest number of medical institutions (n=122), and the top five geographical distribution of participating institutions were in Beijing, Hubei, Guangdong, Zhejiang and Shanghai. The main age of patients recruited in the clinical trial were adults (15-64 years old) / the elderly (≥65 years old) (63.75%), the main type of research was intervention study (75.42%), the main intervention measure was drugs (68.51%), the main source of funding was self-financing (25.00%). 181 intervention studies were at stage 0 (n=70) and Ⅳ (n=49). Conclusion At present, there are a large number of clinical trials in China, but there are few institutional cooperation, the types of intervention measures and trial drugs are not focused, the number of recruits is irrational, and the participating institutions and funding sources are diversified.